Real-world retrospective study on the efficacy and safety of anti-IgE therapy combined with rush immunotherapy in allergic asthma.

Front Allergy · 2025 · PMC12745253 · PMID 41473841

Europe PMC DOI

hedged sentence

0.0540

closest p · 1.1× alpha

0.0540

boldest claim

The sentences

showed a trendp = 0.054so close (0.05 < p ≤ 0.1)

Compared to RIT alone, RIT + Omb-pre significantly reduced SR incidence ( p < 0.05) and showed a trend toward higher target peak concentration completion rates ( p = 0.054).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.